Arnold F Jacobson1, Mark I Travin2. 1. Diagram Consulting, 10 Lio Poele Place, Kihei, HI, 96753, USA. afjacobsonmd@gmail.com. 2. Division of Nuclear Medicine, Montefiore Medical Center, Department of Radiology, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
BACKGROUND: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. METHODS: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. RESULTS: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). CONCLUSIONS: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.
BACKGROUND: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. METHODS: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. RESULTS: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). CONCLUSIONS: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.
Authors: Christoph Rischpler; Kenji Fukushima; Takuro Isoda; Mehrbod S Javadi; Robert F Dannals; Roselle Abraham; Richard Wahl; Frank M Bengel; Takahiro Higuchi Journal: Eur J Nucl Med Mol Imaging Date: 2013-03-29 Impact factor: 9.236
Authors: D M Wieland; L E Brown; W L Rogers; K C Worthington; J L Wu; N H Clinthorne; C A Otto; D P Swanson; W H Beierwaltes Journal: J Nucl Med Date: 1981-01 Impact factor: 10.057
Authors: Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2018-10 Impact factor: 9.236
Authors: David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-29 Impact factor: 9.236
Authors: Gemma Roberts; Rory Durcan; Paul C Donaghy; Sarah Lawley; Joanna Ciafone; Calum A Hamilton; Sean J Colloby; Michael J Firbank; Louise Allan; Nicola Barnett; Sally Barker; Kim Howe; Tamir Ali; George S Petrides; Jim Lloyd; John-Paul Taylor; John O'Brien; Alan J Thomas Journal: Neurology Date: 2021-04-21 Impact factor: 9.910